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Abstract
Background: The NIsin-Controlled gene Expression system NICE of Lactococcus lactis is one of
the most widespread used expression systems of Gram-positive bacteria. It is used in more than
100 laboratories for laboratory-scale gene expression experiments. However, L. lactis is also a
micro-organism with a large biotechnological potential. Therefore, the aim of this study was to test
whether protein production in L. lactis using the NICE system can also effectively be performed at
the industrial-scale of fermentation.
Results: Lysostaphin, an antibacterial protein (mainly against Staphylococcus aureus) from S. simulans
biovar. Staphylolyticus, was used as a model system. Food-grade lysostaphin expression constructs
in L. lactis were grown at 1L-, 300-L and 3000-L scale and induced with nisin for lysostaphin
production. The induction process was equally effective at all scales and yields of about 100 mg/L
were obtained. Up-scaling was easy and required no specific effort. Furthermore, we describe a
simple and effective way of downstream processing to obtain a highly purified lysostaphin, which
has been used for clinical phase I trials.
Conclusion: This is the first example that shows that nisin-regulated gene expression in L. lactis
can be used at industrial scale to produce large amounts of a target protein, such as lysostaphin.
Downstream processing was simple and in a few steps produced a highly purified and active
enzyme.
Background
Lactococcus lactis is a Gram-positive bacterium that is
widely used in food production such as cheese and butter
manufacturing [1]. In the last two decades the physiology
and genetics of this bacterium have been thoroughly char-
acterized [2]. At present several genomes are either com-
pletely sequenced or close to completion [3,4].
Furthermore, L. lactis is easily genetically accessible and a
wide variety of genetic tools have been developed [5].
Because of the genetic accessibility and the ease of its
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oped. Examples are the expression of cytokines and bacte-
rial or viral antigens [6,7], enzymes [8], membrane
proteins [9] and metabolic transformations [10]. These
studies show that L. lactis is a suitable host for applica-
tions beyond its traditional use in food fermentations.
One of the crucial developments has been the construc-
tion of a food grade [11] and regulated gene expression
system based on the regulation mechanism of the nisin A
operon of L. lactis. In this operon the gene product nisin
(a 34 amino acid bacteriocin) activates its own transcrip-
tion at ng/ml amounts [12]. The elements of this regula-
tory system have been isolated and inserted in a suitable
host strain, constituting the powerful regulated gene
expression system NICE (NIsin-Controlled gene Expres-
sion system) [5,13]. The NICE system is widely used on
laboratory scale for research and for over-expression of
genes of interest [8,9,14]. However, experience in large
scale application and fermentation of the NICE system is
very limited.
Lysostaphin is a 25-kD antibacterial protein, produced by
Staphylococcus simulans biovar. Staphylolyticus, that can
hydrolyze the Gly-Gly bonds in the cell wall of the patho-
gens S. aureus and S. epidermidis and thus lyse these bacte-
ria [15,16]. Lysostaphin has been proven to be an effective
agent against the widespread hospital infectious agent S.
aureus [17-19].
In the present study we describe for the first time a large-
scale (3000 L) regulated gene expression process for the
production of a heterologous protein – lysostaphin – in L.
lactis using the NICE expression system. Furthermore, we
also describe the purification of lysostaphin from the
3000-L fermentation batches resulting in a 90% pure
pharmacological intermediate that has been further puri-
fied, formulated and used in clinical phase I studies.
Results
Construction of a lysostaphin expression system in L. lactis
The coding sequence of the lysostaphin gene of S. simulans
biovar. Staphylolyticus, lacking its first two alanine resi-
dues [15], was cloned after PCR amplification into the
NICE vector pNZ8148, resulting in plasmid pNZ1709
(see Table 1). The obtained construct was verified by
nucleotide sequencing. Subsequently, the chlorampheni-
col-resistance cassette was exchanged for the lacF gene of
L. lactis [11], leading to pNZ1710 (Fig. 1A). In this plas-
mid expression of the lysostaphin gene lss is under control
of the nisin-inducible nisA promoter. Furthermore, this
plasmid is selected by a food-grade mechanism, i.e.
growth on lactose, and does not contain an antibiotic-
resistance gene or its remnants. Lysostaphin, a 25-kD anti-
bacterial protein, was produced in the cytoplasm of the
cells. Figure 1B shows an SDS-PAGE image of the intracel-
lular soluble protein fractions of NZ3900 (pNZ1710)
before and after induction with nisin. After induction with
nisin, lysostaphin is accumulated in the cell to about 10%
of the soluble protein fraction, as estimated from SDS-
PAGE (Figure 1B). Lysostaphin was isolated, purified (see
below) and its N-terminal amino acid sequence was deter-
mined to be Thr-His-Glu-His-Ser-Ala [15]. This indicates
that the correct protein was produced, that no significant
intracellular degradation occurred and that the N-termi-
nal formyl-methionine residue was removed.
Development of a fermentation medium and an induction 
scheme for lysostaphin production
In the development of human and animal pharmaceuti-
cals it is important that the product is guaranteed BSE
(Bovine Spongiform Encephalomyelitis) agent-free. All
commercially available pre-formulated media for lacto-
cocci [e.g. M17 [20] contain components of animal origin
such as meat extract and are possible sources for the BSE
agent. Therefore, a new medium based on hydrolysed
plant protein and yeast extract was developed. The key
components of that medium are an entirely plant-based
Table 1: Strains and Plasmids
Bacterial strain/plasmid Properties Reference
Bacteria
Lactococcus lactis subsp. cremoris NZ3900 Integration of nisRnisK in the chromosome; integration of the lac operon in the 
in the chromosome and deletion of lacF resulting in a lactose- negative host 
strain that can be complemented by lacF
[25]
Plasmids
pNZ8148 PnisA, CmR; replicon of rolling circle plasmid pSH71, basic NICE vector, 
derivative of pNZ8048
[12] [26]
pNZ1709 Lysostaphin gene under control of PnisA, CmR; derivative of pNZ8148 This work
pNZ1710 Lysostaphin gene under control of PnisA, lacF; expression vector for food- grade 
expression, selection on growth with lactose; derivative of pNZ1709
This work [11]Page 2 of 9
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least 1%. The peptone chosen, was made from soy protein
digested with the plant derived proteinase papain. Addi-
tionally, the medium contained 5% lactose (certified BSE
free) to allow unlimited growth under pH-regulated
growth conditions. Finally, Mg2+ and Mn2+ were added as
known growth enhancers for lactic acid bacteria [20]. For
details of the composition and sterilization of the
medium see Methods.
Induction of lysostaphin production was carried out at an
optical density at 600 nm of about 1 (light path 1 cm)
(mid exponential growth phase) (0.3 g/L cell dry weight
[21]) by adding nisin (Figure 2). After induction, lys-
ostaphin production proceeded for 6 – 8 hours. Figure 2
shows that upon induction, growth of the culture is
severely inhibited. This is likely the result of lysostaphin
accumulation in the cell that appears to have growth
inhibiting properties (viable plate counts drop within 20
min after induction 3–4 orders in magnitude).
Scale-up of lysostaphin production to 300 L and 3000 L
Lysostaphin production was scaled up from 1-L scale to
300-L scale and eventually 3000-L fermentations. Growth
and induction conditions found at laboratory scale were
directly transferred to the 300-L and 3000-L scale: Induc-
tion at an optical density OD600 = 1 with 10 ng/ml nisin.
Details of media preparation for the larger scales are
described in Methods. Figure 3 shows the growth charac-
teristics of induced cultures of L. lactis carrying the plas-
mid pNZ1710 at all three scales. All three cultures
behaved very similarly, despite the difference in scale of
more than 3 orders of magnitude. The lysostaphin yields
of the 1-L and 3000-L fermentations after induction were
approximately 100 mg/L. Four consecutive 3000-L pro-
duction runs were carried out to produce raw material for
Plasmid bearing the lysostaphin gene and over expression of this geneFigure 1
Plasmid bearing the lysostaphin gene and over expression of this gene. A, plasmid construct for nisin-controlled lys-
ostaphin production. PnisA, nisin-controlled promoter; matLss-2A, coding sequence for mature lysostaphin lacking the first 2 
alanine residues; Term., transcription terminator; repC and repA, replication genes; lacF, food-grade lactose selection marker. B, 
SDS-PAGE showing the intracellular production of lysostaphin upon induction with nisin. 1, molecular weight marker; 2, cell 
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tics of the four fermentation runs were virtually identical.
In each run approximately 300 g lysostaphin (100 mg/L)
were produced and subsequently used as starting material
for purification.
Downstream processing of the 3000-L lysostaphin 
production batch
A downstream processing protocol was designed for the
preparation of a pharmaceutical intermediate that could
be used for further purification and formulation to carry it
into clinical phase I trials.
The basic operations were concentration and washing of
the cells, destruction of the cells by homogenization,
removal of the cell debris, and capturing of the lys-
ostaphin by chromatography.
The fermenter content was concentrated about 20-fold by
filtration (tangential flow) over a 0.8 µm ceramic mem-
brane (3.8 m2) and then 200% diafiltrated to remove
most of the residual medium components. The retentate
was subjected to continuous homogenization at 1400 bar,
80 L/h. The homogenization procedure was repeated
three times to ensure complete release of the intracellular
lysostaphin produced.
The cell debris was then separated from the intracellular
fraction by filtration (tangential flow) over a 0.8 µm
ceramic membrane (3.8 m2). The homogenate was first
concentrated to 100 L and then 300 % diafiltrated to wash
out any lysostaphin associated with the cell debris. The
resulting lysostaphin-containing filtrate of about 400 L
was stored frozen before loading onto the chromatogra-
phy column.
Capturing lysostaphin
A cation-exchange chromatography capture step was
selected based on the relatively alkaline isoelectric point
(pH 9.5) of lysostaphin [16]. Because of superior perform-
ance, the strong exchanger SP-Sepharose FF was chosen
over the weak exchanger CM-Sepharose FF. Optimum lys-
ostaphin binding was found at pH 7.5 in phosphate
buffer. Lysostaphin was eluted using a NaCl step gradient
Growth characteristics of 1-L cultureFigure 2
Growth characteristics of 1-L culture. Culture at 1-L scale of L. lactis NZ3900 containing the lysostaphin expression plas-
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concentrations (Methods) as used for loading (Figure 4A
and 4B show an elution profile and SDS-PAGE analysis).
Since maximum binding of lysostaphin was hindered by
unknown components in the cell extract, the flow-
through was re-fed to the column twice to capture more
than 90% of lysostaphin from the cell extract. Finally, the
eluate was diluted and all captured lysostaphin was
applied to the column at once for an additional recapture
step (Methods). The resulting material was ca. 90% pure
lysostaphin as determined by SDS-PAGE analysis (Meth-
ods). The lysostaphin production yield in the
fermentation was about 100 mg/l. Therefore about 300 g
lysostaphin had been produced in each 3000-L fermenta-
tion run. The mean total yield of the downstream process
was about 120 g, resulting in 40% recovery of the origi-
nally produced lysostaphin.
Discussion
Nisin-regulated gene expression in Lactococcus lactis has
been shown to be an effective and multifunctional tool
[2,5,7,9]. L. lactis has numerous characteristics that make
it an interesting host for industrial-scale heterologous pro-
tein production: it is 100% food grade, including plasmid
selection systems, it produces no endotoxins or other
toxic substances, it produces no inclusion bodies and no
Comparison of growth characteristics of 1-L, 300-L and 3000-L culturesFigure 3
Comparison of growth characteristics of 1-L, 300-L and 3000-L cultures. Culture of L. lactis NZ3900 containing the 
lysostaphin expression plasmid pNZ1710 at 1-L, 320-L and 3000-L scale with induction by 10 ng/mL nisin. As comparison, 
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Purification of the overproduced lysostaphin. A, Typical chromatogram of a lysostaphin capture step. NaCl concentra-
tion (brown line) and absorption at 280 nm (blue line) are indicated. Fractions that were analysed by SDS-PAGE are indicated 
by grey bars underneath. The lysostaphin fraction (F6) is indicated with a black bar. B, SDS-PAGE analysis of the different frac-
tions of the capture chromatography. 1, molecular weight marker; 2, cell extract before loading; 3, flow-through fraction (F3); 
4, 5 and 6, fractions F4, F5 and F7; 7, lysostaphin fraction F6; 8, 9 and 10, fraction F6 diluted 1:2, 1:4 and 1:8.
Fractions:                 F3                                   F4 F5 F6 F7
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tations and produces no extracellular proteinases. With
these characteristics, it can be used for food applications,
as a source of enzymes, for metabolic transformations and
for the production of biologicals. The fact that L. lactis is
food grade also means that cellular components or
enzymes can be used with only partial purification or
directly in the crude cell extract without further purifica-
tion. Despite 10 years of laboratory use of the NICE sys-
tem, we are not aware of any reports that describe the step
to large-scale industrial application of this tool. This paper
describes the successful development and scale-up of a
process for the production of a heterologous protein using
lysostaphin as an example. Lysostaphin is an antibacterial
protein from S. simulans biovar. Staphylolyticus, that has
potential in topical and systemic applications for the
treatment of Staphylococcus aureus infections [17-19]. Lys-
ostaphin is a clear example for the benefits of a regulated
expression system, since constitutive intracellular lys-
ostaphin expression leads to rapid cell death. Another
advantage of regulated gene expression is that the cells can
be pre-grown to a certain cell density before the energeti-
cally costly production of a foreign protein is switched on.
Furthermore, a food-grade plasmid selection system
based on lactose consumption has been used, making the
use, detection and tracing of antibiotics unnecessary. This
food-grade construct allowed the production of a pharma-
ceutical intermediate in a cheaper food-grade production
plant rather than in a cGMP facility. Similarly, such a
process could be used to make other industrially interest-
ing intermediates such as enzymes for food and
(bio)chemical applications, probiotic preparations, etc.
The process described in this paper was first developed at
1-L scale and subsequently transferred to the 300-L and
3000-L scale. This scale-up was without problems, with-
out specific calculations and without changes in the
available equipment. L. lactis is a simple fermentative,
oxygen-tolerating bacterium converting lactose or glucose
into lactic acid. Therefore, no oxygen transfer is needed
during the fermentation. The only condition that needs to
be met is appropriate mixing of the whole culture to
ensure evenly distributed nutrients and effective distribu-
tion of nisin for the induction of gene expression. One sig-
nificant difference exists in the addition of nisin to the
culture at different scales. At laboratory scale this addition
takes a few seconds, while at 3000-L scale it takes 2 – 5
min. Despite the difference in addition times, no adverse
effects on the induction process and lysostaphin produc-
tion were observed.
We carried out four consecutive fermentations at the
3000-L scale. The growth of the culture in all four fermen-
tation runs was nearly identical, as was the final yield of
lysostaphin after purification (about 120 g per batch),
indicating the biological and technical robustness of the
process.
The down-stream processing shows that L. lactis can effec-
tively be separated from the fermentation medium and
that the cell content can be released by high-pressure con-
tinuous homogenization. In the present process three pas-
sages for complete destruction of the cells are used.
Preliminary results show that two passages may be
enough. The cell debris can simply be removed by a sec-
ond filtration step in the same equipment that is used for
the cell separation. After separation of the cell content
from the debris, the product can be used as crude extract
with enriched enzyme activity or different routes can be
followed to further purify or enrich the active component:
ultrafiltration, selective precipitation and chromatogra-
phy. In the present process, lysostaphin was captured on
SP-Sepharose FF in two consecutive steps. We found that
an as yet unknown component in the cell extract ham-
pered binding of lysostaphin to the resin. This obstacle
was overcome by repeated loading of the flow-through to
the same column. The solution of captured lysostaphin
apparently lost the interfering component and could be
completely bound to the resin in one recapture run. Fur-
ther research is needed to identify the interfering com-
pound and to design a process in which lysostaphin can
be captured in a single run.
While 100 mg/L yield is relatively low for bulk produc-
tions, it may be acceptable for specialized productions.
Careful optimization of growth and induction can lead to
considerable yield increases. This was also demonstrated
for lysostaphin were in a separate set of experiments lys-
ostaphin production was optimized and a yield of 300
mg/L was reached [22]. One of the challenges is the devel-
opment of a fermentation process in which this fermenta-
tive organism can be grown to higher cell densities.
The downstream process as a whole consists only of a few
steps and is thereby simple, fast and highly reproducible.
After further optimization it could easily be carried out
within 48 h after the fermentation run, limiting the whole
process to one week from seed culture to product.
Conclusion
The present publication describes for the first time that it
is possible to use the lactic acid bacterium L. lactis for
industrial scale heterologous protein production. Further-
more, we demonstrate that the widely used nisin-control-
led gene expression system NICE is fully operative at this
scale. This opens the way for a food grade alternative
expression system to the commonly used host E. coli.
Other advantages are that L. lactis does not produce endo-
toxins or inclusion bodies, and does not produce sporesPage 7 of 9
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of pharmaceutical, cosmetics, biochemical, food, and feed
applications.
Methods
Bacterial strains and plasmids
Table 1 shows the strain and the plasmids used in this
study. The bacteria were maintained as frozen stock at -
80°C.
Growth media and cultivation conditions
For the genetic construction work the bacteria were rou-
tinely grown in M17 medium [20] fortified with 1%
glucose or 0.5% lactose and 5 µg/ml chloramphenicol for
selection on chloramphenicol resistance.
For 1-L, 300-L and 3000-L fermentations the following
medium was used: 5% lactose (pharmaceutical-grade lac-
tose Lactochem 207, Borculo DOMO Ingredients, Zwolle,
The Netherlands), 1.5% peptone from soy (VWR-Merck,
product number 111932, Amsterdam, The Netherlands),
1% yeast extract (BioSpringer, product number 1105C0/
180, Maisons Alfort, France), 1 mM MgSO4 (VWR-Merck),
0.1 mM MnSO4 (VWR-Merck). For the 1-L scale all ingre-
dients were dissolved in water and the medium was steri-
lized for 20 min at 110°C. For the 300- and 3000-L scale
all ingredients were dissolved in water and subsequently
stream-sterilized (Crepaco, Bryan, Texas, U.S.A.) for 20 s
at 140°C (batch-wise sterilization will cause chemical
reactions in the medium that will inhibit growth of the
bacteria). Bacteria were inoculated at 1 % and grown at
30°C. For 300- and 3000-L fermentations inoculum was
prepared as follows. 2 mL frozen stocks were removed
from -80°C freezer, inoculated into 100 and 300 ml fer-
mentation medium, respectively, and grown under acidi-
fying conditions as standing culture for 16 h. For the 300-
L fermentation, 30 ml of this culture were inoculated into
3 L fermentation medium and cultivated under acidifying
conditions as standing culture for 16 h. For the 3000-L
fermentation, 300 mL were inoculated into 30 L fermen-
tation medium in a 75-L fermentor and cultivated for 16
h with a stirring speed of 50 rpm under acidifying
conditions.
Nisin induction
0.04% nisin powder (Sigma-Aldrich Chemie, Zwijn-
drecht, The Netherlands) was dissolved in 0.05% acetic
acid and precipitated proteins were removed by centrifu-
gation. Cells were grown to an optical density at 600 nm
of 1 (light path 1 cm) (= 0.3 g/L cell dry weight [21]) at
which point 10 ng/ml of nisin (final concentration) was
added. Following the induction, the culture was incu-
bated for 6 – 8 h before harvest. The 3000-L fermentations
were terminated by rapid cooling to 4°C and stored for
about 12 h at this temperature before further processing.
Molecular techniques
Standard genetic techniques were carried out according to
Sambrook et al. [23]. SDS-PAGE was performed according
to Laemmli [24]. N-terminal amino acid sequencing was
outsourced (Protein Sequencing Laboratories, University
of Leiden, Netherlands).
Detection and quantification of lysostaphin
Lysostaphin production was routinely monitored using
SDS-PAGE. The activity of the enzyme was determined
using the Staphylococcus carnosus cell wall degradation
assay [15]. Lysostaphin was quantified using capillary
electrophoresis as described in Mierau et al. [22]. Purity of
lysostaphin was determined from scanning and analysis
of SDS-PAGE gels with a PowerLookIII scanner (UMAX
Systems GmbH, Düsseldorf, Gemany) and the ImageMas-
ter software (GE Healthcare, formerly Amersham Bio-
sciences, Rosendaal, The Netherlands).
Equipment for fermentation, filtration and 
homogenization
For 1-L, 30-L, 300-L, and 3000-L fermentations, stirred,
temperature- and pH-regulated tank fermentors were used
(1 L: Applicon fermentor with Biocontroller ADI 1030,
Applicon, Frederiksberg, Denmark; 30L and 300 L:
Chemap fermentors, Chemap AG, Volketswil, Switzer-
land; 3000 L: custom made fermentor). Stirring was car-
ried out with a propeller blade stirrer at approximately 50
rpm, to ensure proper mixing of the base and of nisin.
During the fermentation, temperature and base
consumption were recorded to monitor the process. To
determine the cell density of the cultures and to find the
time point for induction, samples were taken at regular
intervals and the OD at 600 nm (light path 1 cm) was
determined.
For microfiltration, a one-stage filtration installation was
used with a Ceraver ceramic membrane of 0.8 µm pore
size and 3.8 m2 surface (Membralox, Pall, East Hills, New
York, U.S.A.). The flow rate was approximately 330 L/h.
Concentrated cell suspensions were disintegrated using a
continuous homogenization process at 1400 bar with a
flow rate of about 80 L/h (Homogenizer 10.51 VH, APV,
Hendrik Ido Ambacht, The Netherlands). To prevent over-
heating, the pressure-reduction nozzle was cooled with ice
water.
Chromatography
Large-scale chromatography was carried out with a Bio-
processor (max. flow rate of 120 L/h) and a BPG300 col-
umn (Amersham Biosciences, Roosendaal, The
Netherlands). For the separation 14.1 L Sepharose Fast
Flow resin (17-0792-04, Amersham Biosciences) was
used, resulting in a bed height of 20 cm. The sample wasPage 8 of 9
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with 0.4 M NaH2PO4 pH 7.5. The following buffers and
cleaning solutions were used: Equilibration buffer, 50
mM NaH2PO4 pH 7.5; Elution buffer, 50 mM NaH2PO4 +
0.5 M NaCl pH 7.5; Regeneration buffer, 50 mM
NaH2PO4 + 1 M NaCl pH 7.5; Cleaning solution, 1 M
NaOH. A standard chromatography run was carried out as
follows. The column was equilibrated with 2 volumes
equilibration buffer at 120 L/h, the pH-adjusted sample
was loaded at 100 L/h, the loaded column was washed
with 3 volumes equilibration buffer at 120 L/h, lys-
ostaphin was eluted with 2 column volumes elution
buffer at 120 L/h and the column was cleaned with 1 col-
umn volume cleaning solution at 50 L/h. Finally, the col-
umn was regenerated with 2 column volumes
regeneration buffer at 120 L/h. This process was repeated
for all subsequent runs. Since the whole sample of about
400 L could not be loaded at one time (Results), it was
divided into four portions of approximately 100 L each.
For recapture, the following buffers and solutions were
used: Equilibration buffer, 12.5 mM NaH2PO4 + 75 mM
NaCl pH 7.0; Elution buffer, 25 mM NaH2PO4 + 0.25 M
NaCl pH 7.0, Cleaning solution and regeneration buffer
were as mentioned above. For recapture, the eluate of the
capture step was desalted using diafiltration and the pH
was adjusted to pH 7.0. The column was equilibrated with
2 column volumes of equilibration buffer at 120 L/h, the
sample was loaded at 100 L/h, the column was washed
with 3 volumes equilibration buffer at 120 L/h and the
product was eluted with 2 column volumes elution buffer.
Cleaning and regeneration was done as described above.
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